Pancreatic Ductal Organoids React Kras Dependent to the Removal of Tumor Suppressive Roadblocks
Pancreatic ductal adenocarcinoma (PDAC) is still the Achilles heel in modern oncology, with an increasing incidence accompanied by a persisting high mortality. The developmental process of PDAC is thought to be stepwise via precursor lesions and sequential accumulation of mutations. Thereby, current...
Saved in:
Main Authors: | Lukas Perkhofer, Melanie Engler, Johann Gout, Frank Arnold, Mareen Morawe, Markus Breunig, Thomas Seufferlein, Alexander Kleger, Pierre-Olivier Frappart |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2019-01-01
|
Series: | Stem Cells International |
Online Access: | http://dx.doi.org/10.1155/2019/2079742 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Multiomic quantification of the KRAS mutation dosage improves the preoperative prediction of survival and recurrence in patients with pancreatic ductal adenocarcinoma
by: Won-Gun Yun, et al.
Published: (2025-01-01) -
Mechanisms of KRAS inhibitor resistance in KRAS-mutant colorectal cancer harboring Her2 amplification and aberrant KRAS localization
by: Kohei Maruyama, et al.
Published: (2025-01-01) -
Vitamin K‐dependent gamma‐carboxyglutamic acid protein 1 promotes pancreatic ductal adenocarcinoma progression through stabilizing oncoprotein KRAS and tyrosine kinase receptor EGFR
by: Zheng Wu, et al.
Published: (2025-01-01) -
A short history of »Kras«
by: Andrej Kranjc
Published: (2018-12-01) -
Targeting KRAS‐mutant pancreatic cancer through simultaneous inhibition of KRAS, MEK, and JAK2
by: Satoru Miyazaki, et al.
Published: (2025-02-01)